http://www.nice.org.uk/newsroom/pressreleases/DiabeticMacularOedemaNotRecommended.jsp
NICE, the healthcare guidance body, has not recommended ranibizumab (Lucentis, Novartis) for the treatment of diabetic macular oedema (DMO).
The independent Appraisal Committee concluded that the evidence presented by the manufacturer did not provide a true reflection of the cost-effectiveness for ranibizumab monotherapy compared with the current standard treatment for people with DMO, laser photocoagulation, which uses heat to seal ocular blood vessels.
NICE, the healthcare guidance body, has not recommended ranibizumab (Lucentis, Novartis) for the treatment of diabetic macular oedema (DMO).
The independent Appraisal Committee concluded that the evidence presented by the manufacturer did not provide a true reflection of the cost-effectiveness for ranibizumab monotherapy compared with the current standard treatment for people with DMO, laser photocoagulation, which uses heat to seal ocular blood vessels.
